Young Adults With Acute Lymphoblastic Leukemia Have an Excellent Outcome With Chemotherapy Alone and Benefit From Intensive Postinduction Treatment: A Report From the Children's Oncology Group
- 1 November 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (31), 5189-5194
- https://doi.org/10.1200/jco.2008.20.8959
Abstract
Purpose Patients 16 to 21 years of age with acute lymphoblastic leukemia (ALL) have an inferior outcome compared with younger children, leading some medical oncologists to advocate allogeneic stem-cell transplantation in first remission for these patients. We examined outcome for young adults with ALL enrolled onto the Children's Cancer Group (CCG) 1961 study between 1996 and 2002. Patients and Methods CCG 1961 entered patients with ALL 1 to 21 years of age with initial WBC count ≥ 50,000/μL and/or age ≥ 10 years. Randomly assigned therapies evaluated the impact of postinduction treatment intensification on outcome. We examined outcome and prognostic factors for 262 young adults with ALL. Results Five-year event-free and overall survival rates for young adult patients are 71.5% (SE, 3.6%) and 77.5% (SE, 3.3%), respectively. Rapid responder patients (< 25% bone marrow blasts on day 7) randomly assigned to augmented therapy had 5-year event-free survival of 81.8% (SE, 7%), as compared with 66.8% (SE, 6.7%) for patients receiving standard therapy (P = .07). One versus two interim maintenance and delayed intensification courses had no significant impact on event-free survival. WBC count more than 50,000/μL was an adverse prognostic factor. Conclusion Young adult patients with ALL showing a rapid response to induction chemotherapy benefit from early intensive postinduction therapy but do not benefit from a second interim maintenance and delayed intensification phase. Given the excellent outcome with this chemotherapy, there seems to be no role for the routine use of allogeneic stem-cell transplantation in first remission for young adults with ALL.This publication has 14 references indexed in Scilit:
- What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesBlood, 2008
- Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trialsPediatric Blood & Cancer, 2007
- Prognostic Impact of Age in Children and Adolescents with Acute Lymphoblastic Leukemia: Data from the Trials ALL-BFM 86, 90, and 95Klinische Padiatrie, 2005
- Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemiaBritish Journal of Haematology, 2005
- Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the NetherlandsLeukemia, 2004
- Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?Cancer Treatment Reviews, 2004
- Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 TrialsJournal of Clinical Oncology, 2003
- Augmented Post-Induction Therapy for Children with High-Risk Acute Lymphoblastic Leukemia and a Slow Response to Initial TherapyThe New England Journal of Medicine, 1998
- Young adults 16-21 years of age at diagnosis entered on childrens cancer group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatmentCancer, 1993
- Presenting features and treatment outcome of adolescents with acute lymphoblastic leukemia.1990